MAPT and Cognitive impairment: Real sample validation with human serum from 14 healthy individuals, 14 mild cognitive impairment patients, and 14 dementia patients revealed a significant correlation between tau-441 levels and cognitive impairment severity, demonstrating the potential of this non-invasive platform for early dementia diagnosis.